Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AR goggles for surgeons: a new way to remove liver tumors?

NCT ID NCT07630610

Symptom relief Sponsor: Navari Surgical AB Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests an augmented reality (AR) system that overlays a tumor's image onto the liver during keyhole surgery. Six adults scheduled for liver tumor removal will participate. The goal is to see if the AR guidance helps surgeons remove tumors more completely and safely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Augmented reality system
What this could lead to
If successful, this could make liver tumor surgery safer and more precise, reducing complications.
What could go wrong
This is a very early, small pilot study with only 6 participants, so results may not apply broadly. The technology may not improve outcomes as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 6 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject scheduled for liver tumor resection of one or more tumors. One tumor per surgery is always chosen as the study tumor and will be removed first. 2. The tumor must be susceptible to uncomplicated wedge resection within one to two segments. 3. The tumor has been diagnosed as malignant or is suspected to be malignant based on imaging or clinical assessment. 4. The tumor's size should not exceed 50 mm in any orientation. 5. Subject 18 years or older. 6. Subject is able to read and understand the Patient information which is written in Swedish. 7. Subject has given consent to study participation. Exclusion Criteria: 1. Unresectable tumors. 2. Not uncomplicated resection (e.g. central resection, re-resection, or large resection, defined as resection of more than two segments). 3. Subject is not suitable for MIS, as judged by the principal investigator. 4. Subject with reduced kidney function. 5. Subject with known hypersensitivity to contrast agents. 6. Subject considered unable to comply with hospital's instructions, at the discretion of the principal investigator. 7. Subject is not suitable for inclusion in the opinion of the investigator. 8. Pregnant women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver and intrahepatic bile duct neoplasm Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.